本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。时代的尘埃终于还是如大山一样,压到了泰格医药的头上。3月27日,泰格医药发布了2024年年报。这份年报堪称其上市以来最惨淡的成绩单:全年营收66.03亿元,同比下降10.58%;归母净利润4.05亿元,同比暴跌79.99%;扣非净利润8.55亿元,同比减少42.13%。这是泰格医药自2012年上市以来,首次出现营业收入下滑的情况,也是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.